NCT04370223 (COVID-OZONE) is a Phase 3 clinical trial of Ozone auto-hemotherapy in COVID-19 Pneumonia, sponsored by Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta.

Who is sponsoring NCT04370223?

NCT04370223 is sponsored by Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta.

What drugs are being tested in NCT04370223?

Interventions in NCT04370223: Ozone auto-hemotherapy.

What condition does NCT04370223 study?

NCT04370223 studies COVID-19 Pneumonia.

Is NCT04370223 still recruiting?

NCT04370223 is currently status unknown. Last updated 9 June 2020.

Last reviewed 2020-06-09 · How we verify

NCT04370223: COVID-OZONE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ozone Auto-hemotherapy for COVID-19 Pneumonia

Status unknown Phase 3 Last updated 9 June 2020

What this trial tests

Phase 3 trial testing Ozone auto-hemotherapy in COVID-19 Pneumonia in 208 participants. Status unknown.

Timeline

25 May 2020

Primary endpoint
25 October 2020

25 December 2020

Quick facts

Lead sponsor	Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	208
Start date	25 May 2020
Primary completion	25 October 2020
Estimated completion	25 December 2020
Sites	10 locations across Spain

Drugs / interventions tested

Ozone auto-hemotherapy — full drug profile →

Conditions studied

COVID-19 Pneumonia — all drugs for COVID-19 Pneumonia →

Sponsor

Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

Who can join

Adults 18 to 90, any sex, with COVID-19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, randomized, controlled, open-label clinical trial testing the use of ozone auto-hemotherapy in hospitalized patients with Covid-19 pneumonia. Eligible patients will be randomly assigned to receive either ozone auto-hemotherapy plus standard treatment, or standard treatment alone. Patients in the ozone auto-hemotherapy group will receive treatment mixing 100-200ml of blood with ozone at a concentration of 40 μg / mL with a gas volume of 200 ml. Treatment will occur every 12h during 5 days. Standard treatment will be the one used in each hospital participating in the trial. All analyses will be done according to the intention-to-treat principle

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19.
Barh D, Tiwari S, Weener ME, Azevedo V, et al · · 2020 · cited 57× · PMID 33131530 · DOI 10.1016/j.compbiomed.2020.104051
Insights on the mechanisms of action of ozone in the medical therapy against COVID-19.
Chirumbolo S, Valdenassi L, Simonetti V, Bertossi D, et al · · 2021 · cited 29× · PMID 34020394 · DOI 10.1016/j.intimp.2021.107777
The Relationship between Ozone and Human Blood in the Course of a Well-Controlled, Mild, and Transitory Oxidative Eustress.
Tricarico G, Travagli V. · · 2021 · cited 22× · PMID 34943049 · DOI 10.3390/antiox10121946
Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.
Ranaldi GT, Villani ER, Franza L. · · 2020 · cited 7× · PMID 33004712 · DOI 10.4103/2045-9912.289462

Verify or expand the search:

Other recruiting trials for COVID-19 Pneumonia

Currently open trials in the same condition.

NCT06601998 — Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. · recruiting
NCT06501599 — AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes · recruiting
NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting

Other Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta trials

Trials by the same sponsor.

NCT06869941 — Adipose Tissue Gene Expression and Metabolomics Links to the Gut Microbiome-brain Axis · recruiting
NCT07502053 — Evaluation of the Perfusion of the Pancreatic Remnant With Indocyanine Green and Its Impact on the Reduction of Pancreat · NA · recruiting
NCT06442215 — Selection of Surgical Technique in Rectal Cancer · recruiting
NCT06220045 — Comparing PP and PVDF Meshes in Midline Laparotomy Closure for High-risk Colorectal Surgery. Impact on Incisional Hernia · NA · recruiting
NCT06135857 — Electromuscular Stimulation Therapy as a Prophylactic Method to Reduce Thromboses Related to PICC Catheters in Patients · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04370223 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Last refreshed: 9 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04370223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing